Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicted Impacts of Booster, Immunity Decline, Vaccination Strategies, and Non-Pharmaceutical Interventions on COVID-19 Outcomes in France.
Pageaud S, Eyraud-Loisel A, Bertoglio JP, Bienvenüe A, Leboisne N, Pothier C, Rigotti C, Ponthus N, Gauchon R, Gueyffier F, Vanhems P, Iwaz J, Loisel S, Roy P, On Behalf Of The CovDyn Group Covid Dynamics. Pageaud S, et al. Among authors: gueyffier f. Vaccines (Basel). 2022 Nov 28;10(12):2033. doi: 10.3390/vaccines10122033. Vaccines (Basel). 2022. PMID: 36560443 Free PMC article.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients presenting sepsis-induced immunosuppression: The GRID randomized controlled trial.
Vacheron CH, Lepape A, Venet F, Monneret G, Gueyffier F, Boutitie F, Vallin H, Schwebel C, Maucort-Boulch D, Friggeri A; GRID Study Group. Vacheron CH, et al. Among authors: gueyffier f. J Crit Care. 2023 Dec;78:154330. doi: 10.1016/j.jcrc.2023.154330. Epub 2023 May 31. J Crit Care. 2023. PMID: 37267804 Clinical Trial.
Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia.
Terzić V, Levoyer L, Figarella M, Bigagli E, Mercier N, De Gastines L, Gibowski S, Trøseid M, Demotes J, Olsen IC, Hites M, Ader F, Lopez JRA, Mentré F, Espérou H, Costagliola D, Røttingen JA, Poissy J, Rozé JC, Warris A, O'Leary J, Fernandes RM, Assoumou L, Hankard R, Turner MA, Yazdanpanah Y, Diallo A; EU-Response safety group; c4c safety group. Terzić V, et al. Br J Clin Pharmacol. 2023 Apr;89(4):1318-1328. doi: 10.1111/bcp.15669. Epub 2023 Feb 8. Br J Clin Pharmacol. 2023. PMID: 36680782 Free article. Review.
Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health.
Vanier A, Fernandez J, Kelley S, Alter L, Semenzato P, Alberti C, Chevret S, Costagliola D, Cucherat M, Falissard B, Gueyffier F, Lambert J, Lengliné E, Locher C, Naudet F, Porcher R, Thiébaut R, Vray M, Zohar S, Cochat P, Le Guludec D. Vanier A, et al. Among authors: gueyffier f. BMJ Evid Based Med. 2024 Jan 19;29(1):1-5. doi: 10.1136/bmjebm-2022-112091. BMJ Evid Based Med. 2024. PMID: 36788020 Free PMC article. No abstract available.
Project rebuild the evidence base (REB): A method to interpret randomised clinical trials and their meta-analysis to present solid benefit-risk assessments to patients.
Boussageon R, Blanchard C, Charuel E, Menini T, Pereira B, Naudet F, Kassai B, Gueyffier F, Cucherat M, Vaillant-Roussel H. Boussageon R, et al. Among authors: gueyffier f. Therapie. 2023 Jul-Aug;78(4):353-365. doi: 10.1016/j.therap.2022.10.008. Epub 2022 Oct 20. Therapie. 2023. PMID: 36371260
233 results